Webinar: Interim Results from FORWARD-53 Study of WVE-N531 in Duchenne Muscular Dystrophy
by: Parent Project Muscular Dystrophy
PPMD hosted a community webinar with Wave Life Sciences on Wednesday, October 2, 2024. The webinar featured Wave’s President and CEO and Chief Development Officer, who presented an update on the recently announced interim results from the company’s ongoing Phase 2 FORWARD-53 study of WVE-N531 in individuals with Duchenne who are amenable to exon 53 skipping.
by: Parent Project Muscular Dystrophy
